Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Vilya Therapeutics is designing macrocycle drug candidates.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Salveson, P. J. et al. Science https://doi.org/10.1126/science.adk1687 (2024).
Rettie, S. A. et al. Preprint at bioRxiv https://doi.org/10.1101/2024.11.18.622547 (2024).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M. Editor’s pick: Vilya Therapeutics. Nat Biotechnol 43, 1409–1410 (2025). https://doi.org/10.1038/s41587-025-02782-x
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02782-x
